Status:

COMPLETED

Leukapheresis for Research on HCV-Coinfected Patients

Lead Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions:

Hepatitis C

HIV Infections

Eligibility:

All Genders

18+ years

Brief Summary

This study will collect quantities of white blood cells from patients infected with the hepatitis C virus (HCV) for research on the interactions between HCV and the human immunodeficiency virus (HIV) ...

Detailed Description

Hepatitis C virus (HCV) and Hepatitis B (HBV) infection are known to cause morbidity and mortality especially among those who are coinfected with Human Immunodeficiency virus (HIV). HCV infected indiv...

Eligibility Criteria

Inclusion

  • INCLUSION CRITERIA FOR BOTH GROUPS:
  • Adult (18 years old or older)
  • Either monoinfected with HCV or coinfected with HCV and HIV
  • Willingness to give informed consent.
  • Willing to undergo genetic testing
  • Willing to have samples stored for future research.
  • Must have a referring physician or clinic that will continue to provide medical care.
  • Note: An HCV/HIV coinfected individual is defined as any individual with all the following: 1) Positive ELISA and western blot test for HIV, and 2) Positive serology and/or positive HCV RNA test; An HCV monoinfected individual is defined as any individual with all of the following: 1) Positive serology and/or positive HCV RNA test, and 2) Negative ELISA test for HIV
  • INCLUSION CRITERIA FOR GROUP 1:
  • Must be willing and able to make follow up visits for leukapheresis and blood draws at least once in the next 6 months
  • INCLUSION CRITERIA FOR GROUP 2:
  • Must be referred by a physician for the purposes of confirming HCV diagnosis, complications from HCV, or standard HCV treatment management.
  • EXCLUSION CRITERIA FOR BOTH GROUPS
  • Have any other condition, which the investigator considers a contraindication to study participation.
  • EXCLUSION FOR GROUP 1:
  • Evidence of liver failure on liver biopsy, abdominal ultrasound, or liver function blood tests
  • Receiving HCV therapy at the time of enrollment
  • Platelet count \< 50,00 per mL
  • Hematocrit \< 28 percent.

Exclusion

    Key Trial Info

    Start Date :

    January 14 2004

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    June 9 2015

    Estimated Enrollment :

    327 Patients enrolled

    Trial Details

    Trial ID

    NCT00076427

    Start Date

    January 14 2004

    End Date

    June 9 2015

    Last Update

    October 6 2017

    Active Locations (4)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (4 locations)

    1

    Family and Medical Counseling Service

    Washington D.C., District of Columbia, United States

    2

    Unity Health Care/Walker Jones

    Washington D.C., District of Columbia, United States

    3

    Whitman Walker Clinic

    Washington D.C., District of Columbia, United States

    4

    National Institutes of Health Clinical Center, 9000 Rockville Pike

    Bethesda, Maryland, United States, 20892